← Back to Search

FDG and DHT PET Imaging for Prostate Cancer

Led By Michael Morris, M.D., Ph.D.
Research Sponsored by Memorial Sloan Kettering Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Screening 3 weeks
Treatment Varies
Follow Up 2 years
Awards & highlights

Study Summary

This trial will use PET scans with a radiotracer to see if it can more accurately find where prostate cancer has spread in the body.

Who is the study for?
Men with confirmed prostate cancer showing progression through new bone lesions, increased soft tissue disease, or rising PSA levels. They must have visible cancer signs on CT, MRI, or bone imaging and functionally adequate kidneys and liver. Those with severe kidney issues, past severe reactions to the PET scan tracers, or significant liver dysfunction cannot join.Check my eligibility
What is being tested?
The trial is testing two PET scan radiotracers: [18F]-Fluoro-2-Deoxy-D-Glucose (FDG) and [18F] Dihydro-Testosterone (FDHT), to see if they can more accurately detect where prostate cancer has spread in the body compared to current methods.See study design
What are the potential side effects?
Potential side effects may include allergic reactions to the tracers used for PET scans. However, since this study focuses on diagnostic procedures rather than treatment drugs, fewer side effects are expected compared to therapeutic trials.


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
To study the accumulation and biodistribution of FDHT in patients with progressive prostate cancer. The accumulation and location of FDHT activity will be assessed on a site by site basis and correlated with radionuclide bone scan, CT and MRI.
Secondary outcome measures
The kinetics, metabolism, and biodistribution will be assessed.
To correlate the accumulation of 18FDHT to 18FDG.
To study changes in 18FDHT accumulation over time in patients treated with: Castration and other hormones, Chemotherapy, Agents directed toward the androgen receptor
+2 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: 1Experimental Treatment1 Intervention
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone

Find a Location

Who is running the clinical trial?

Memorial Sloan Kettering Cancer CenterLead Sponsor
1,935 Previous Clinical Trials
588,555 Total Patients Enrolled
132 Trials studying Prostate Cancer
51,774 Patients Enrolled for Prostate Cancer
Michael Morris, M.D., Ph.D.Principal InvestigatorMemorial Sloan Kettering Cancer Center

Media Library

[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Clinical Trial Eligibility Overview. Trial Name: NCT00588185 — N/A
Prostate Cancer Research Study Groups: 1
Prostate Cancer Clinical Trial 2023: [18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Highlights & Side Effects. Trial Name: NCT00588185 — N/A
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone 2023 Treatment Timeline for Medical Study. Trial Name: NCT00588185 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the aggregate figure of participants in this study?

"Affirmative. According to the clinicaltrials.gov website, this experiment is currently seeking volunteers and was first published on February 1st 2003 before being modified most recently on April 13th 2022. 300 participants must be sourced from a single medical institution."

Answered by AI

Are there still vacancies available for people interested in participating in this clinical trial?

"Data from clinicaltrials.gov shows that this research is presently recruiting volunteers, with the first posting on February 1st 2003 and most recent amendment occurring April 13th 2022."

Answered by AI
~23 spots leftby Feb 2026